IFIH1 and dermatomyositis: We further estimated the power of five to seven candidate metabolite biomarkers to differentiate DM, PM, and ASS patients from HCs, between different subtypes of IIM patients, and MDA5 + and MDA5- DM patients in the discovery/validation cohorts by random forest.